Institute of Orthopedic, Chinese PLA General Hospital, Beijing, China.
Department of Sports Medicine, Chinese PLA General Hospital, Beijing, China.
Orthop Surg. 2023 Feb;15(2):549-562. doi: 10.1111/os.13662. Epub 2023 Jan 17.
Cartilage defect is a common pathology still lacking a unified treating option. The purpose of this retrospective study is to evaluate the safety, efficacy, and clinical and radiological outcome of cartilage restoration of knee joint with allogenic next-generation Matrix-Induced Autologous Chondrocyte Implantation (MACI) for the first time, as well as the correlation between postoperative clinical and radiological outcomes and preoperative patient history and demographics.
From July 2014 to August 2020, 15 patients who went through cartilage restoration with allogenic next-generation MACI were included in this study. Patient demographics and PROM including the International Knee Documentation Committee (IKDC) subjective knee score, Lysholm score, Tegner Activity Scale (TAS), and Knee Injury and Osteoarthritis Outcome Score (KOOS) were obtained preoperatively, at 3, 6, 12 months postoperatively and the last follow-up using an online questionnaire platform. MOCART 2.0 score was calculated at the last follow-up. Analysis of variance (ANOVA) was used to compare PROM pre- and post-operation, with two-tailed p < 0.05 defined as statistical significant. Pearson correlation coefficient was used to evaluate correlation between the PROM and MOCART 2.0 score at the last follow-up with patients demorgraphics.
All patients were followed for an average of 66.47 ± 24.15 months (range, 21-93). All patients were satisfied with the outcome of the surgery and no complication was reported at the end of the study. No significant improvement was observed until 1 year after the implantation, except for IKDC score at 6 months. All PROM showed significant improvement 1 year post-op except for Lysholm score and TAS, which also increased significantly at the time of the last follow-up. Pearson correlation coefficient showed that the size of the defect, before or after debridement, was significantly negatively correlated with final KOOS-Pain (before debridement: r = -0.57, p < 0.05; after debridement: r = -0.54, p < 0.05) and KOOS-Symptoms score (before debridement: r = -0.66, p < 0.05; after debridement: r = -0.67, p < 0.05). The MOCART 2.0 score was found significantly and negatively correlated with BMI (r = -0.60, p < 0.05), and significantly and positively correlated with Lysholm score (r = 0.70, p < 0.05).
The next generation MACI with autologous chondrocyte and allogenic chondrocyte ECM scaffold could be used to treat focal articular cartilage defect in the knee joint safely and efficiently with lasting promising outcomes for more than 5 years. The size of the defects should be considered the most negatively correlated parameters influencing the postoperative clinical outcomes.
软骨缺损是一种常见的病理,仍然缺乏统一的治疗方法。本回顾性研究的目的是评估全膝关节同种异体下一代基质诱导自体软骨细胞植入术(MACI)治疗膝关节软骨缺损的安全性、有效性和临床及影像学结果,并分析术后临床和影像学结果与术前患者病史和人口统计学的相关性。
从 2014 年 7 月至 2020 年 8 月,共纳入 15 例接受同种异体下一代 MACI 软骨修复的患者。采用在线问卷调查平台,在术前、术后 3、6、12 个月和末次随访时,收集患者人口统计学数据和 PROM,包括国际膝关节文献委员会(IKDC)主观膝关节评分、Lysholm 评分、Tegner 活动量表(TAS)和膝关节损伤和骨关节炎结果评分(KOOS)。末次随访时计算 MOCART 2.0 评分。采用方差分析(ANOVA)比较术前和术后 PROM,以双侧 p<0.05 为统计学显著差异。采用 Pearson 相关系数评估末次随访时 PROM 与 MOCART 2.0 评分与患者人口统计学的相关性。
所有患者平均随访 66.47±24.15 个月(范围 21-93)。所有患者对手术结果均满意,研究结束时无并发症报告。除 6 个月时 IKDC 评分外,植入后直到 1 年未见明显改善。除 Lysholm 评分和 TAS 外,所有 PROM 在术后 1 年均显著改善,且在末次随访时也显著增加。Pearson 相关系数显示,缺陷的大小,无论是术前还是术后,均与终末 KOOS-疼痛(术前:r=-0.57,p<0.05;术后:r=-0.54,p<0.05)和 KOOS-症状评分(术前:r=-0.66,p<0.05;术后:r=-0.67,p<0.05)呈显著负相关。MOCART 2.0 评分与 BMI 呈显著负相关(r=-0.60,p<0.05),与 Lysholm 评分呈显著正相关(r=0.70,p<0.05)。
自体和同种异体软骨细胞外基质支架的下一代 MACI 可安全有效地治疗膝关节局灶性关节软骨缺损,5 年以上效果持久。缺陷的大小应被视为影响术后临床结果的最负相关参数。